Commercial RisksRisks include failure to achieve commercial success due to market size, penetration rate, or competition, and potential dilution risk.
Financial PerformanceFor fiscal 1Q25 ending on January 31, 2025, net loss was $3.2M, or ($0.10) per share.
Regulatory RisksRisks include failure of cancer vaccine and/or CAR-T therapy in clinical trials and failure to secure regulatory approval.